As previously reported, Argus upgraded Integra LifeSciences to Buy from Hold with a $25 price target. Shares have jumped 65% since the announcement on May 5 that Stuart Essig, who is chairman, would be returning to the CEO position that he previously held, notes the analyst, who adds that change in the executive suite gives the firm confidence that \"an earnings turnaround is at hand.\" The company, which recently topped Q1 EPS expectations and raised guidance, should be able to meet customer demand for tissue and skin regenerative products with production issues resolved, the analyst added.
